In the collaboration LSPC will apply its proprietary proteomic discovery technologies to identify novel targets from patient samples provided by Biosite Discovery, Biosite’s program aimed at the discovery of new markers of disease.
Under the collaboration, Biosite intends to utilize the novel targets with its proprietary Omniclonal antibody technology to develop diagnostics for numerous disorders, including cardiovascular, cerebrovascular, and neurological disorders.
Biosite will retain target rights for the development and commercialization of FDA-approved in vitro diagnostics resulting from the alliance, while LSPC will retain target rights for other potential therapeutic and diagnostic uses.
The companies will share in revenues from resulting products.
Biosite Discovery is a development program dedicated to the discovery of novel targets and corresponding antibodies primarily in the areas of cancer, cerebrovascular, cardiovascular and infectious disease.
The program utilizes a broad base of technologies designed to provide biotechnology and pharmaceutical customers with an advantage in performing target characterization and validation.
Large Scale Proteomics Corporation, a subsidiary of Large Scale Biology Corporation with headquarters in Vacaville, California, is a provider of proteomic technologies to the life sciences industry, and is located in Rockville, MD.